Side effects do not occur when the appropriate dose and admission is strictly for the course. In some cases, or an overdose can be side effects: a headache, toxic effects in the kidneys due to the delay large amounts of fluid in the body, hair loss, hair growth in the body and face, increased hostility. At that time, the operation of their hormones, which can lead to involuntary changes can be stopped. The same can be disorders of the gastrointestinal tract (diarrhea, nausea, abdominal), elevated robots sebaceous glands rash all over the body, deepening of the voice, both men, and women.
Denosumab is a human monoclonal antibody . As with all therapeutic proteins, there is potential for immunogenicity. Using an electrochemiluminescent bridging immunoassay, less than 1% (55 out of 8113) of patients treated with Prolia for up to 5 years tested positive for binding antibodies (including pre-existing, transient, and developing antibodies). None of the patients tested positive for neutralizing antibodies, as was assessed using a chemiluminescent cell-based in vitro biological assay. No evidence of altered pharmacokinetic profile, toxicity profile, or clinical response was associated with binding antibody development.